Resistance Profile, Terbinafine Resistance Screening and MALDI-TOF MS Identification of the Emerging Pathogen

Roelke De Paepe1, Anne-Cécile Normand2, Silke Uhrlaß3

  • 1Mycology and Aerobiology Department, Sciensano, 1050, Brussels, Belgium. roelke.depaepe@sciensano.be.

Mycopathologia
|March 14, 2024
PubMed

Insights

Emerging Trichophyton indotineae strains show high terbinafine resistance due to gene mutations. Rapid identification is crucial for treating severe fungal infections effectively.

Area of Science:

  • Medical Mycology
  • Antimicrobial Resistance
  • Molecular Diagnostics

Background:

  • Trichophyton indotineae causes severe dermatophytoses and often exhibits terbinafine resistance.
  • Effective treatment necessitates understanding T. indotineae resistance profiles and rapid identification methods.

Purpose of the Study:

  • To evaluate a screening medium for terbinafine resistance in T. indotineae.
  • To confirm resistance via antifungal susceptibility testing (AST) and identify resistance mechanisms.
  • To assess MALDI-TOF MS for rapid and accurate T. indotineae identification.

Main Methods:

  • Screening medium test on 20 T. indotineae strains.
  • Antifungal susceptibility testing (AST) for terbinafine and eight other antifungal drugs.
  • DNA sequencing of the squalene epoxidase gene.
  • MALDI-TOF Mass Spectrometry (MS) for species identification.

Main Results:

  • 45% of T. indotineae strains were terbinafine-resistant.
  • Terbinafine-resistant strains also showed elevated resistance to naftifine and amorolfine.
  • Gene sequencing revealed missense point mutations (F397L or L393F) in the squalene epoxidase gene causing resistance.
  • MALDI-TOF MS accurately identified T. indotineae strains but could not differentiate susceptible from resistant ones.

Conclusions:

  • A significant proportion of T. indotineae strains are terbinafine-resistant, linked to specific gene mutations.
  • MALDI-TOF MS is a valuable tool for rapid T. indotineae identification, aiding clinical management.
  • Further methods are needed to distinguish terbinafine-resistant strains for targeted therapy.